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DERIVATIVES OF N-CHLORO-N-METHYL 
GLUCAMINE AND N-CHLORO-N-METHYL 
GLUCAMINE ESTERS 
This application is a divisional of application Ser. No. 
08/736,913, ?led Oct. 25, 1996 now US. Pat. No. 5,753, 
701. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
The present invention relates to N-chloro-N-methyl glu 
camine and N-chloro-N-methyl glucamine esters, and their 
use as agents for Water disinfection and as mild oxidizing 
agents for the radiolabeling of oxidation-sensitive organic 
molecules. 
2. Description of the Related Art 
Chloramines are Widely knoWn as useful Water disinfect 
ing agents. Among the most popular chloramine Water 
disinfecting agents is halaZone (p-N,N 
dichlorosulfamylbenZoic acid). While effective, halaZone 
suffers from some important disadvantages, including its 
strong, unpleasant chlorine odor, its sensitivity to light, its 
relatively loW solubility in Water, and, perhaps most 
importantly, the formation of potentially carcinogenic chlo 
rinated hydrocarbons Which are generated as the result 
reaction With impurities commonly found in Water supplies. 
In vieW of these disadvantages, it should be apparent that 
there still exists a need in the art for improved Water 
disinfecting agents. 
Chloramines, in particular chloramine-T (CAT) are fre 
quently used in the radiolabeling of organic molecules by 
halogenation, for example, as described in US. Pat. No. 
5,424,402 (“the ’402 patent”), the contents of Which are 
incorporated herein by reference. According to the method 
of the ’402 patent an organic molecule may be radiolabeled 
by reaction With 12512. Normally, the 12512 is released from 
its sodium salt by oxidation With chloramine-T. The disad 
vantage of this procedure is that residual CAT in the reaction 
mixture frequently causes oxidative decomposition of the 
organic molecule rendering the procedure useless. There 
exists a need for a mild oxidiZing agent that is capable of 
releasing molecular halogens from their salts Without oxi 
diZing organic molecules to be labeled. 
N-methyl glucamine is knoWn in the prior art as a 
solubiliZing agent in the formulation of intravenous 
pharmaceuticals, enabling high concentrations of pharma 
ceuticals to be administered. HoWever, prior to the present 
invention the particular substituted glucamines of the 
present invention, and their use in the puri?cation of Water, 
Was not knoWn. 
SUMMARY OF THE INVENTION 
Accordingly, a major object of the present invention is to 
meet the art-recogniZed need for a safe, effective and inex 
pensive method for disinfection of Water supplies. 
Advantageously, the compounds of the present invention 
minimiZe the formation of the carcinogenic chlorinated 
hydrocarbons Which are currently generated as the result of 
disinfection With halaZone and similar agents. Furthermore, 
these compounds satisfy the need for an agent that can be 
conveniently used in households to disinfect Water, espe 
cially in developing nations, as a replacement for HalaZone. 
The present inventors have found that chlorination of 
N-methyl glucamine yields N-chloro-N-methyl glucamine, 
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a poWerful germicidal agent. The compounds of the present 
invention have the folloWing structure: 
Wherein R is —H or —COR2, Wherein R2 is loWer alkyl. 
These compounds are useful as disinfecting agents, particu 
larly for disinfecting Water supplies. When used as a 
disinfectant, the compounds of the present invention gener 
ate N-methyl glucamine, a very safe agent, in parts per 
millions. 
A further object of the present invention is to meet the 
need for a mild oxidiZing agent for use in radiohalogenation 
procedures involving oxidation-sensitive organic molecules 
and similar substrates. The present inventors have observed 
that the N-chloro derivatives of secondary amines, such as 
N-methyl glucamine and its esters, are much Weaker oxi 
diZing agents than N-chloro compounds, such as 
chloramine-T and halaZone. When used in radiohalogena 
tion procedures, N-chloro secondary amines do not oxidiZe 
most organic molecules. 
With the foregoing and other objects, advantages and 
features of the invention that Will become hereinafter 
apparent, the nature of the invention may be more clearly 
understood by reference to the folloWing detailed descrip 
tion of the preferred embodiments of the invention and to the 
appended claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1: UV absorbance spectra of NaOCl (1), penta-O 
acetyl-N-chloro-N-methylglucamine (NCMG)(2), and 
penta-O-acetyl-N-methylglucamine (NMG)(3). 
FIG. 2: Fraction of L-tyrosine (Tyr), mono-3-iodo-L 
tyrosine (Iodo-Tyr), and 3,5-diiodo-L-tyrosine (Diiodo-Tyr) 
for four methods of iodinating L-tyrosine in phosphate 
buffer (0.01M, pH 7.2). 
FIG. 3: Peak areas of leucine enkephalin (Leu-Enk), 
iodoleucine enkephalin Iodo-Leu-Lek), and diiodoleucine 
enkephalin (Diiodo-Leu-Enk) for six methods of iodinated 
leucine enkephalin in phosphate buffer. 
FIG. 4: Susceptibility of L. pneumophila AA100 to dif 
ferent NCMGE concentrations. 
FIG. 5: Kinetics of killing of L. pneumophila by 105 ppm 
NCMGE. 
FIG. 6: Susceptibility of L. pneumophila AA100 in 
co-culture With H. vermiformis to 105 ppm NCMGE in 30 
minutes incubation. 
FIG. 7. Kinetics of multiplication of L. pneumophila 
AA100 Within H. vermiformis. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS OF THE 
INVENTION 
The present inventors have found that chlorination of 
N-methyl glucamine yields N-chloro-N-methyl glucamine, 
a poWerful germicidal agent. The compounds of the present 
invention comprise the folloWing structure: 
5,985,239 
wherein R is —H or —COR2, wherein R2 is loWer alkyl. 
These compounds are useful as disinfecting agents, particu 
larly for disinfecting Water supplies. When used as a 
disinfectant, the compounds of the present invention gener 
ate N-methyl glucamine, a very safe agent, in parts per 
millions. 
The compounds of the present invention are also useful as 
mild oxidiZing agents for use in radiohalogenation proce 
dures involving oxidation-sensitive organic molecules, in 
particular oxidation-sensitive biomolecules and similar sub 
strates. The present inventors have observed that the 
N-chloro derivatives of secondary amines, such as N-methyl 
glucamine and its esters, are much Weaker oxidiZing agents 
than N-chloro compounds, such as chloramine-T and hala 
Zone. When used in radiohalogenation procedures, N-chloro 
secondary amines do not oxidiZe most biomolecules. 
The compounds of the present invention may be synthe 
siZed by any means knoWn to the skilled artisan. Preferably, 
the compounds of the present invention are prepared from 
N-methylglucamine, Which may be obtained commercially 
or may be synthesiZed according to any method knoWn to 
the skilled artisan. For example, N-methylglucamine may be 
synthesiZes from D-glucose and methylamine according to 
the method of Karrer (Helv. Chim. Acta 20:83 (1937), the 
contents of Which are incorporated herein by reference). 
The present invention also provides compositions of 
matter comprising one or more of the compounds of the 
present invention and a suitable carrier therefor. These 
compositions may also include other disinfectant 
compounds, including chlorinating compounds such as 
halaZone, or other antibiotic agents. Compositions according 
to the present invention may be formulated in any manner 
suitable for use as a disinfectant. For example, compositions 
of the present invention may be provided as aqueous solu 
tions or suspensions. More preferably, the compositions of 
the present invention are provided in solid form. Particularly 
preferred are tablet and granular forms of the composition of 
the present invention, Which provide for easy storage and 
handling. Tablets and granules may be formulated according 
to any means knoWn in the art. For the purposes of the 
present invention tablets may be of any convenient siZe; 
granules are small grains of the composition of the present 
invention; preferably, said grains are betWeen tWo and four 
millimeters in diameter. 
The present invention also provides a method of disin 
fecting Water comprising adding the compounds or compo 
sitions of the present invention in an amount suf?cient to 
disinfect the Water. For the purposes of the present 
invention, disinfection encompasses killing bacteria and 
protoZoans living in the Water to be disinfected. Preferably, 
the compounds or compositions of the present invention Will 
be added to the Water to be disinfected such that the ?nal 
concentration of the compounds of the present invention in 
the Water Will be at least 10 parts per million (ppm), more 
preferably from 60—200 ppm, most preferably 105 ppm. 
The present invention also provides a method for non 
destructively radiolabeling biomolecules by halogenation. 
The method of the present invention is advantageously 
applied to radiolabeling of oxidation-sensitive organic 
molecules, particularly oxidation-sensitive biomolecules. 
The method of the present invention comprises 
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(a) reacting a compound according to the present inven 
tion With a radiolabeled halide salt and an organic 
molecule Which is desired to be radiolabeled such that 
said radiolabeled halogen reacts directly With said 
organic molecule to produce a radiohalogenated 
organic molecule; and 
(b) recovering said radiohalogenated organic molecule. 
The method of the present invention may advantageously be 
carried out in the presence of a buffer. In a preferred 
embodiment, the method of the present invention provides 
that the compound according to the present invention and 
the radiolabeled halide salt are mixed together ?rst, such that 
the radiolabeled halide salt is converted into molecular 
radiolabeled halogen; then, the organic compound to be 
labeled is added to the mixture. 
For use in the present invention, the radiolabeled halogen 
salt is preferably selected from the group consisting of 
sodium, potassium, lithium, rubidium, cesium, magnesium, 
calcium, and ammonium salts. Particularly preferred are 
sodium halogen salts, most preferably sodium iodide. 
The folloWing examples are presented in order to more 
fully illustrate the preferred embodiments of the invention. 
They should in no Way be construed, hoWever, as limiting 
the broad scope of the invention. 
EXAMPLE 1 
Preparation of Penta-O-Acetyl-N-Chloro-N 
Methylglucamine (NCMGE) 
a. Synthesis of Penta-O-Acetyl-N-Methylglucamine 
(NMGE): 
CHZb 
NHZh c104 
CH2c 
O H°—C—O—C—CH3“ 
dH2c—o—c—cH3a 
Penta-O-Acetyl-N-Met_hylglucan1ine Perchlorate 
N-methylglucamine(10 g) Was dissolved in 7.4 g (4.4 ml) 
of (70%) perchloric acid in a round bottom ?ask. Ethyl 
acetate (500 ml) Was added. The solution Was stirred, and 73 
g of acetyl chloride Was added dropWise. The solution Was 
left stirring at room temperature for four days until a White 
solid Was formed. The resulting White solid Was ?ltered and 
Washed With ether and recrystalliZed from acetone/ 
petroleum ether mixture and dried overnight in a vacuum 
oven. The melting point of the solid Was 148—150° C.; MW 
504.45; 1H-NMR (DMSO-d?) (FIG. 1): 62.05 (15H, m, 
protons a), 2.56 (3H, S, protons b), 3.13 (2H, m, protons c), 
4.20 (2H, m, protons d), 4.98 (1H, proton e), 5.05 (1H, m, 
proton f, 5.27 (2H, protons g), 8.47 (2H, broad s, protons h). 
b. Synthesis of Penta-O-Acetyl-N-Chloro-N 
Methylglucamine (NCMGE): 
5,985,239 
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CH; 0 
O 
H 
Penta-O-acetyl-N-methylglucamine (3.0 g) Was dissolved 
in Water and the pH of the solution Was adjusted 6.0 by 
addition of 2N NaOH solution. Chlorine gas Was bubbled 
into the solution for a feW minutes until a White solid Was 
formed. The solid Was ?ltered and Washed With Water and 
dried in a vacuum oven. The melting point Was 77—79° C.; 
MW 439.45; 1H-NMR (CDCl3): 62.08 (15H, m, protons a), 
2.93 (3H, S, protons b), 3.05 (2H, m, protons c), 4.20 (2H, 
m, protons d), 5. 10 (IH, proton e), 5.40 (IH, m, proton f), 
5.44 (2H, protons g). 
Elemental analysis: Found: C,46.24; H, 5.9 1; N, 3.17; Cl, 
8.15%. Calculated for C17H26O1ONCl: C, 46.41; H, 5.9 1; N, 
3.18; Cl, 8.08%. 
The product Was also identi?ed by UV spectrophotometry 
(FIG. 1). 
EXAMPLE 2 
The Use of NCMGE in Radiolabeling Techniques 
1. Chemical Stability of a Model Amino Acid 
(1-Aminocyclo-hexane Carboxylic Acid) in the Presence of 
Chloramine-T, NCMG, and NCMGE. 
N-chloro amino acids, such as N-chloro-l-amino 
cyclohexane carboxylic acid, Which are formed by chlori 
nation of the amine group, are very unstable (Hussain et al. 
1995 Analyt. Biochem 224:221—226; AWad et al. 1990 J. 
Pharm Sci. 79:1121—1122; the contents of both of these 
articles are incorporated herein by reference). Their decom 
positions are associated With loss of chlorine titer. In order 
to determine Whether NCMG and NCMGE chlorinate 
1-aminocyclohexanecarboxylic acid, iodometric titration 
Was used to folloW the reaction. 
A solution of 1-aminocyclohexanecarboxylic acid con 
taining 2><10_3M Was prepared in 0.1M phosphate buffer 
(pH 7.0) and equilibrated for 2 minutes at 25° C. For the 
Chloramine-T (CAT) experiments, a solution of CAT 
(1><10_3 M) in Water Was freshly prepared and equilibrated 
for 2 minutes at 25° C. Equal volumes (10.0 ml) of the tWo 
solutions Were mixed (t=0) and stored at 25° C. Aliquots of 
the mixture (4.0 ml) Were assayed periodically using stan 
dard iodometric titration; i.e. addition of excess KI and back 
titration of the liberated iodine With sodium thiosulfate using 
starch as an indicator. A control experiment Was carried out 
by folloWing the chlorine titer of a solution of CAT in 
phosphate buffer in the absence of the amino acid. 
For the experiments With NCMG and NCMGE, a solution 
of either NCMG or NCMGE (1><10_3M) in phosphate buffer 
(0.1M, pH 7.0) Was freshly prepared and equilibrated for 2 
minutes at 25° C., and a 10.0 ml aliquot Was mixed With an 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
6 
equal volume of 1-aminocyclohexanecarboxylic acid 
(0.02M), (t=0). The mixture Was stored at 25° C. and 
assayed periodically by titration, as described above. A 
control experiment Was conducted in the absence of the 
amino acid. 
2. Iodination of L-tyrosine 
Solutions: 
Phosphate buffer (0.01M, pH 7.4): A total of 5.0 g of 
NaCl, 0.1 g KCI, 0.57 g Na2HPO4, and 0.1 g KHZPO4 Were 
dissolved in 500 ml of glass distilled Water. The pH of the 
solution Was adjusted to 7.4 With either NaOH or HCl, as 
needed. 
L-tyrosine solution: A total of 25 mg of L-tyrosine Was 
dissolved in 100 ml of phosphate buffer. 
Sodium Iodide solution: A total of 207 mg of sodium 
iodide Was dissolved in 100 ml phosphate buffer. 
Penta-O-acetyl-N-chloro-N-methylglucamine solution 
(NCMGE): A total of 141 mg of NCMGE Was dissolved in 
100 ml of phosphate buffer (0.01M, pH 7.4). 
Experimental: 
The HPLC system for analysis Was as folloWs: 
Mobile phase=Distilled Water/methanol/85% phosphoric 
acid=(550/450/8). 
FloW rate=1.0 ml/min. 
Detector UV Wavelength 254 nm 
Temperature=ambient. 
Method I: A total of 0.2 ml of L-tyrosine solution, 0.02 ml 
sodium iodide solution, and 0.108 ml of phosphate buffer 
Were mixed in a tube for tWo minutes, then 0.172 ml of 
NCMGE solution Was added (t=0), and 50 pl samples Were 
WithdraWn at 2 and 15 minutes and injected directly into the 
HPLC. 
Method II: A total of 0.2 ml of L-tyrosine solution, and 
0.02 ml of sodium iodide solution Were mixed in a tube for 
2 minutes, then 0.780 ml of NCMGE solution Was added, 
and 50 pl samples Were WithdraWn at 2 and 15 minutes and 
injected directly into the HPLC. 
3. Iodination of leucine enkephalin 
Solutions: 
Phosphate buffer (0.01M, pH 7.4), sodium iodide 
solution, and NCMGE solution Were the same as those for 
the iodination of tyrosine. 
Leucine enkephalin solution: A total of 8.9 mg of leucine 
enkephalin Was dissolved in 10 ml of phosphate buffer 
(0.01M, pH 7.4). 
Experimental: 
The HPLC system for analysis Was described above 
(Section 2). The conditions Were the same as those described 
above for the analysis of iodinated tyrosine products, except 
the mobile phase Was (0.1M NaH2PO4/Methanol=1/1) and 
the detector UV Wavelength Was set at 270 nm. 
Method I: A total of 0.2 ml of leucine enkephalin, 0.020 
ml sodium iodide solution, and 0.083 ml of phosphate buffer 
Were mixed in a tube for 2 minutes, then 0.172 ml of 
NCMGE solution Was added (t=0). At the end of the reaction 
(2 and 15 minutes), 25 pl of 20% sodium thiosulfate solution 
Was added and 50 pl samples Were WithdraWn and injected 
directly into the HPLC. The addition of sodium thiosulfate 
Was found necessary to decompose the residual NCMGE 
because NCMGE interfered With the enkephalin peaks in the 
HPLC. 
Method II: A total of 0.2 ml of leucine enkephalin and 
0.020 ml sodium iodide Were mixed in a tube for 2 minutes 
and NCMGE solution (0.755 ml) Was added (t=0). At the 
end of the reaction (2 and 15 minutes), 25 pl of 20% sodium 
thiosulfate solution Was added and 50 pl samples Were 
WithdraWn and injected directly into the HPLC. 
5,985,239 
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4. Iodination of L-tyrosine 
To determine Whether NCMGE Would have practical 
activity in the radiohalogenation of amino acid, L-tyrosine, 
Was selected as a model and compared With the method 
employed by Hussain et. al (1995 Analyt. Biochem 
224:221—226), the contents of Which are incorporated herein 
by reference. The results in FIG. 2 shoW that When NCMGE 
Was used, the yield of the tWo iodinated species of 
L-tyrosine Were signi?cantly greater With both 2 and 15 
minutes incubation times than those obtained With CAT and 
iodobead and close to that of N-chloromorpholine. 
5. Iodination of leucine enkephalin 
To determine Whether NCMGE Would have practical 
utility in radiohalogenation of small peptide, leucine 
enkephalin Was selected as a model substrate for comparison 
of iodination procedures employing CAT solution and 
NCMGE. The methods Were tested using 2 and 15 minute 
incubation times. The results in FIG. 3 shoW that When 
NCMGE Was used, the yield of the tWo iodinated leucine 
enkephalin species Were signi?cantly greater With both 2 
and 15 minutes incubation times. When CAT Was used alone 
With a 15 minutes incubation time, the yield of the apparent 
diiodinated species (labeled diiodo leuenk in FIG. 3) Was 
signi?cantly smaller than When NCMGE Was present. This 
appears to be the result of decomposition of leucine 
enkephalin, as indicated by the smaller amount of all species 
folloWing 15 minutes exposure to CAT alone (see FIG. 3). 
EXAMPLE 3 
The germicidal activity of Penta-O-acetyl-N-chloro 
N-methylglucamine (NCMGE) 
The antimicrobial activity of NCMGE Was examined in 
the folloWing experiments: 
A. Legionella pneumophila 
Legionella pneumophila strain AA100 Was inoculated 
into buffered charcoal-yeast extract (BCYE) agar plates and 
incubated for 48 hours at 37° C. The bacteria Were sus 
pended into 0.01M phosphate buffer pH 7.4 to an optical 
density of 0.7—0.8 at 550 nm. 
15 pl of bacterial suspension Was mixed With 7.0 ml 
0.01M phosphate buffer (pH 7.4) containing disinfectant 
compounds as listed in Table I. The concentration of bacteria 
in this suspension Was approximately 1 million bacteria/ml. 
After 30 minutes the activity of the disinfectant compounds 
Was quenched With 0.4 ml 0.01M sodium bisul?te. 
TABLE 1 
Names and concentrations of N-chloro compounds used in germicidal 
experiment. 
Compound Concentration 
Control 0 
Monochloramine (NHZCI) 10 
Penta-O-acetyl-N-chloro-N-methylglucamine 30 
Penta-O-acetyl-N-chloro-N-methylglucamine 60 
Penta-O-acetyl-N-chloro-N-methylglucamine 105 
TWo aliquots of 20 pl of the ?nal solution of each of the 
above Was diluted in 0.01M phosphate buffer to approximate 
bacterial concentrations of 103 and 102/100 pl. 100 pl of the 
tWo ?nal dilutions Were groWn on BCYE agar plates that 
Were incubated at 37° C. for three days. At the end of the 
three day incubation period, the colony forming unit Was 
enumerated. Another experiment Was conducted against the 
serogroups of Legionella pneumophila us ing NCMGE in a 
concentration of 105 ppm. 
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B. Coincubation of Hartmannella vermiformis and 
Legionella pneumophila. 
Amoebae H. vermiformis Were suspended in assay 
medium to give a ?nal concentration of 105 cell per ml. 
Tissue culture ?asks containing amoebae Were inoculated 
With Legionella pneumophila, suspended in Pucks’ saline to 
give a ?nal concentration of 103 bacteria per ml, and 
incubated at 37° C. 1.2 ml aliquots Were WithdraWn imme 
diately and 1, 2, 3, 5, and 7 days after inoculation. Of the 1.2 
ml, 0.2 ml Was cultured on BCYE agar plates in order to 
folloW the increase in the number of bacteria. The remaining 
1.0 ml Was centrifuged at 8000 rpm for 5 minutes. The 
bacterial pellet Was Washed tWice With sterile deioniZed 
Water. The pellet Was then suspended in 1.0 ml to 105 ppm 
NCMGE solution for 30 minutes. After 30 minutes, tWo 20 
pl aliquots of this NCMGE solution Were diluted in 0.01M 
phosphate buffer to an approximate bacterial concentration 
of 103 and 102/100 pl. 100 pl of these tWo dilutions Were 
deposited on BCYE agar plates and incubated at 37° C. for 
three days. At the end of the three day period, the colony 
forming units Were enumerated. 
Results: 
The antimicrobial activity of N-chloramine penta-O 
acetyl-N-chloro-N-methylglucamine (NCMGE) Was exam 
ined against Legionella pneumophila ?rst using the mini 
mum inhibitory concentration (MIC) method. This method 
is based on incubation of the organism for 30 minutes at 
different NCMGE concentrations. The results shoWn in FIG. 
4 indicate that the MIC for NCMGE is 105 ppm. Second the 
antimicrobial activity Was examined using the contact ger 
micidal efficiency (CGE). This method involves examining 
the bactericidal activity of NCMGE (105 ppm) at different 
incubation times. After each time interval, the chlorine 
activity of NCMGE Was quenched by 0.01M sodium 
bisul?te. The results in FIG. 5 indicate that the shortest time 
for Which groWth of L. pneumophila is not observed Was 
found to be 20 minutes. 
The antimicrobial activity of NCMGE (105 ppm) Was 
also examined against a serogroups of L. pneumophila 
compared to a control of 1000 cfu and incubation time of 30 
minutes. The results shoWn in Table II shoW that this 
NCMGE concentration kills all the strains of Legionella to 
Which it Was exposed. 
TABLE II 
Susceptibility of L. pneumophila serogroups to 105 ppm NCMGE 
compared to a control of 1000 cfu and incubation time of 30 minutes 
Serogroup Strain % Survival 
13 Philadelphia 1 0 
2 Togus 1 0 
3 Bloomington 2 0 
4 Los Angeles 1 0 
5 Dallas 1 0 
6 Chicago 2 0 
7 Chicago 8 0 
8 Concord 3 0 
9 IN 23 0 
10 Leiden 1 0 
11 797-PA-H 0 
12 570-Co-H 0 
13 82A3105 0 
3The serogroups of L. pneumophila are distinguished by their lipopolysac 
charide antigen. 
Finally, the antimicrobial activity of NCMGE (105 ppm) 
Was tested against a coculture of Legionella pneumophila 
and H. vermiformis in Which the L. pneumophila typically 
become more resistant to chlorine. The results shoWn that 
5,985,239 
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NCMGE (105ppm) killed 95% of the bacteria at day 4 (FIG. 
6), the time at which L. pneumophila typically reach their 
maximum growth (as shown in FIG. 7). The results in FIG. 
6 also demonstrate that NCMGE has a powerful sustained 
antimicrobial activity. 
While the invention has been described and illustrated 
herein by references to various speci?c material, procedures 
and examples, it is understood that the invention is not 
restricted to the particular material, combinations of 
material, and procedures selected for that purpose. Numer 
ous variations of such details can be implied and will be 
appreciated by those skilled in the art. 
What is claimed is: 
1. A method of labeling organic molecules comprising 
(a) reacting an organic molecule with a radiolabeled 
halide salt and a substituted N-chloro-N-methyl glu 
camine compound comprising the following structure: 
10 
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wherein R is —H or COR2, and wherein R2 is lower alkyl, 
wherein that said radiolabeled halogen reacts directly with 
said organic molecule to produce a radiohalogenated organic 
molecule; and 
(b) recovering said radiohalogenated organic molecule. 
2. The method of claim 1, wherein said radiolabeled 
halogen salt is selected from the group consisting of sodium, 
potassium, lithium, rubidium, cesium, magnesium, calcium, 
and ammonium halide salts and mixtures thereof. 
3. The method of claim 2, wherein said radiolabeled 
halogen salt is a radiolabeled sodium halogen salt. 
4. The method of claim 3, wherein said radiolabeled 
sodium halogen salt is radiolabeled sodium iodide. 
5. The method of claim 1, wherein said reaction takes 
place in the presence of a buffer. 
6. The method of claim 1, wherein said organic molecule 
is a biomolecule. 
7. The method of claim 1, wherein the substituted 
N-chloro-N-methyl glucamine compound is miXed with the 
radiolabeled halogen salt prior to miXing with the organic 
compound to be labeled. 
* * * * * 
